Simulations Plus, Inc. (SLP)

Market Cap	359.67M
Revenue (ttm)	80.38M
Net Income (ttm)	-63.19M
Shares Out	20.13M
EPS (ttm)	-3.15
PE Ratio	n/a
Forward PE	40.90
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,578
Open	17.87
Previous Close	17.79
Day's Range	17.87 - 17.87
52-Week Range	12.39 - 37.67
Beta	1.00
Analysts	Buy
Price Target	26.80 (+49.97%)
Earnings Date	Dec 1, 2025

About SLP

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models,...

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Jun 18, 1997
• Employees: 247
• Stock Exchange: NASDAQ
• Ticker Symbol: SLP
• Website: https://www.simulations-plus.com

Financial Performance

In 2024, Simulations Plus's revenue was $70.01 million, an increase of 17.52% compared to the previous year's $59.58 million. Earnings were $9.95 million, a decrease of -0.07%.

Analyst Summary

According to 8 analysts, the average rating for SLP stock is "Buy." The 12-month stock price target is $26.8, which is an increase of 49.97% from the latest price.

Price Target

$26.8

(49.97% upside)

Analyst Consensus: Buy